News Headlines

  1. Penalties And Bans For Defective Vaccines

    Chinese authorities have penalized Changchun Changsheng Life Sciences Limited and its executives over illegalities related to making defective human rabies vaccine.

  2. Cambrex Expands Analytical Capabilities At Its High Point, NC Site

    Cambrex Corporation, the leading manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), and finished dosage forms, recently announced that it is investing $1M at its High Point, NC site to fit out 1,300 sq. ft. of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project.

  3. Lonza To Establish Strategic Biomanufacturing Base In China Using GE Healthcare Solution

    Lonza recently announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou (CN).

  4. WuXi AppTec Expands Site In California For Pharmaceutical R&D Services

    WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces the expansion of its facilities in San Diego, California.

  5. SGS To Expand Bioanalytical Testing Capabilities In France At Its Poitiers Laboratory

    SGS, a leading biopharmaceutical analytical and bioanalytical contract solutions provider, recently announced that it is investing €3.5M to undertake a two-phase expansion project at its laboratory in Poitiers, France, to implement a 50% increase in bioanalytical capabilities at the site by 2020.

  6. OnDosis And Recipharm Partner To Advance A Novel Treatment Regimen For ADHD

    Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.

  7. Catalent Invests $14M To Expand Biologics Packaging Capabilities Following Twentieth Commercial Drug Approval At Bloomington, Indiana Site

    Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that following the site’s twentieth commercial product approval, it is investing nearly $14M to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility.

  8. Celltrion And Teva Announce FDA Approval Of TRUXIMA (rituximab-abbs), A Biosimilar To RITUXAN, For Three Non-Hodgkin’s Lymphoma Indications

    Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. recently announced that the U.S. Food and Drug Administration (FDA) has approved TRUXIMA (rituximab-abbs), a monoclonal antibody (mAb) biosimilar to RITUXAN (rituximab) for the treatment of adult patients in three indications: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL) as a single agent.

  9. Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology For ADC Manufacturing

    Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.

  10. Sun Pharmaceutical To Acquire Pola Pharma In Push For Japanese Expansion

    Sun Pharmaceutical Industries agreed to buy smaller rival Pola Pharma in Japan, as Indian drugmakers seek to create a niche in markets outside the U.S.